Hypothesis

Beta‑hydroxybutyrate (βHB) does not merely act as an HDAC inhibitor; it simultaneously stimulates the NAD+ salvage pathway via increased NAMPT expression, creating a transient NAD+ boost that supports sirtuin‑mediated stress resistance. With prolonged ketosis, this boost triggers a feedback inhibition of NAMPT (through elevated NADH/NAD+ ratio and sirtuin‑dependent deacetylation of NAMPT), leading to a programmed decline in NAD+ that conserves resources and shifts cellular ambition from growth to maintenance. Thus, NAD+ decline during ketosis is an adaptive, hormetic response rather than a passive breakdown, and exogenous NAD+ supplementation would blunt the longevity benefits of βHB by preventing this feedback.

Mechanistic Reasoning

1. βHB → HDAC inhibition → chromatin relaxation at the Nampt promoter – HDAC inhibition by βHB increases acetyl‑histone levels, facilitating transcription factor binding (e.g., FOXO3, Nrf2) to the Nampt promoter, raising NAMPT mRNA and enzyme activity. This aligns with observations that βHB extends lifespan through HDAC inhibition and requires SIR‑2.1/DAF‑16 FOXO pathways [[https://pmc.ncbi.nlm.nih.gov/articles/PMC4169858/]].
2. Transient NAD+ surge fuels sirtuin activity – Elevated NAMPT raises intracellular NAD+, activating SIRT1 and SIRT3, which deacetylate metabolic enzymes and promote mitochondrial efficiency and autophagy, contributing to the early phase of hormesis.
3. Feedback inhibition via NADH accumulation and SIRT‑mediated NAMPT deacetylation – Sirtuin activation consumes NAD+, producing NADH. A high NADH/NAD+ ratio allosterically inhibits NAMPT, while SIRT‑dependent deacetylation reduces NAMPT stability. This creates a self‑limiting loop that drives NAD+ levels back down after an initial peak.
4. Adaptive NAD+ decline reduces biosynthetic ambition – Lower NAD+ limits PARP‑driven DNA repair and favors sirtuin‑dependent stress pathways, shifting the cell from a proliferative, anabolic state to a maintenance mode. This mirrors the seed idea that NAD+ decline reflects a budget cut when the future is deemed less worth funding.
5. Antagonism of exogenous NAD+ – Supplying NAD+ (e.g., via NR or NMN) would sustain high NAD+ levels, preventing the feedback‑driven decline, thereby locking cells in a growth‑oriented state and diminishing the hormetic benefits of βHB.

Testable Predictions

• Prediction 1: In C. elegans and mouse models, βHB treatment will produce a biphasic NAD+ curve: an early rise (0–6 h) followed by a decline (12–24 h) that correlates with NAMPT expression dynamics.
• Prediction 2: Genetic or pharmacological inhibition of NAMPT (e.g., with FK866) will abolish the early NAD+ surge and prevent βHB‑induced lifespan extension, despite intact HDAC inhibition.
• Prediction 3: Chronic βHB feeding will increase hepatic NADH/NAD+ ratio and SIRT‑dependent NAMPT deacetylation; mutants lacking the SIRT deacetylation site on NAMPT will show blunted NAD+ decline and reduced longevity benefits.
• Prediction 4: Exogenous NAD+ supplementation (NR/NMN) co‑administered with βHB will flatten the NAD+ biphasic response and significantly attenuate βHB‑mediated lifespan extension in both invertebrates and vertebrates.

Experimental Approach

1. Metabolite tracking: Use LC‑MS/MS to quantify NAD+, NADH, and βHB in tissues at multiple time points after βHB administration in wild‑type and Nampt‑heterozygous mice.
2. Genetic tools: Employ liver‑specific Nampt knockout and NAMPT deacetylation‑resistant (K→R) knock‑in mice to dissect the feedback arm.
3. Lifespan assays: Measure median and maximal lifespan in C. elegans (WT, sir‑2.1 mutants) and mice under four conditions: control, βHB alone, NAD+ booster alone, βHB+NAD+ booster.
4. Readouts: Assess HDAC activity (fluorometric assay), Nampt promoter acetylation (ChIP‑qPCR for H3K9ac), SIRT activity, and downstream stress markers (SOD‑2, FOXO nuclear localization).

Falsifiability

If experiments show that βHB does not elevate NAMPT expression or NAD+ early, or that NAMPT inhibition fails to suppress βHB’s longevity effects, the hypothesis would be refuted. Conversely, demonstrating that NAD+ supplementation consistently abolishes βHB‑induced lifespan extension would confirm the adaptive feedback model.

This framework integrates the epigenetic actions of ketone bodies with NAD+ metabolism, offering a clear, falsifiable mechanism by which NAD+ decline can be a purposeful, hormetic adaptation rather than a mere biomarker of aging.